// App-Quantinova.ai

: Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®

Researchers

Presenter

  • Jeffrey A Gilreath

Principal Investigators

  • Tsewang Tashi

  • Soo Jin Kim

  • Kimberly Hickman

  • Josef T. Prchal

Medical Centers

  • Department of Pharmacotherapy, Huntsman Cancer Institute, University of Utah, Park City, UT

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

  • Division of Hematology and Hematologic Malignancies, University of Utah School of Medicine, Salt Lake City, UT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Polycythemia vera

  • Acute Leukemia

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • MDS1 And EVI1 Complex Locus

  • Ribophorin I

Drug/Treatment

  • Peginterferon alfa-2a

  • Pegylated interferon alfa-2b

  • Interferon

  • Hydroxyurea

  • Hydroxycarbamide

  • Ropeginterferonum alfa 2b

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • NCT01259856

  • NCT01259817

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved